//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
ProfilePosts









Loading...
This interdisciplinary research represents nothing less than a tour de force by Ryan P. Cantwell Chater, and a great collaborative effort between the labs of Robert Vandenberg, Christopher Cioffi, Megan O'mara, Mike Michaelides, Sarasa Mohammadi and myself.
Pedersen, C. N., Yang, F., Ita, S., ..., Mortensen, O. V., Nissen, P., Shahsavar, A. (2024). Cryo-EM structure of the dopamine transporter with a novel atypical non-competitive inhibitor bound to the orthosteric site. J Neurochem, onlinelibrary.wiley.com/doi/10.1111/...
🚨My new team at @ipbstoulouse.bsky.social in France currently have an open, fully-funded PhD position 🧑‍🔬👩‍🔬to study membrane proteins & transporters of therapeutic interest using cryo-EM & biophysics.🧊🔬🦠 #StructuralBiology #MicroSky Please share 🤝 For more details 👇
Apr 24, 2025
May 9, 2025
May 21, 2025
Kien-Lam Ung
Our findings provide proof-of-concept for the rational design of GlyT2 inhibitors and a clear avenue for novel treatments of chronic neuropathic pain.
For 47 years, Iranians have risen up thousands of times to reclaim the greatness they lost. In these final moments of their fight, stand with them as they take back their country's freedom. #IranRevolution #KingRezaPahlavi #IranRevolution2026 #DigitalBlackoutIran
We are grateful for the support from: @lundbeckfonden.bsky.social @novo-nordisk.bsky.social @ NIDA
Apr 24, 2025
We show that RPI-GLYT2-82 is efficacious at alleviating pain in mouse models of neuropathic pain with no mechanism-based side effects tested at doses up to 5 times the maximal analgesic dose, or addiction liability at up to 3 times the maximal analgesic dose.
The Interactive Fly
Apr 24, 2025
5mo